文献速递妇科

铂耐药卵巢癌中Mirv与周疗紫杉醇序贯顺序对缓解的影响

Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?
PubMed 文献 · Gynecol Oncol · 2026-07-10

该单中心回顾性研究纳入62例接受过Mirv和周疗紫杉醇的铂耐药卵巢癌患者,比较两种药物使用顺序对缓解率的影响。Mirv的ORR为34%,周疗紫杉醇的ORR为69%;两种药物的缓解率均不因序贯顺序不同而有显著差异。

要点

  • 铂耐药卵巢癌中Mirv与周疗紫杉醇的使用顺序不影响各自缓解率。
  • Mirv总体ORR为34%,周疗紫杉醇总体ORR为69%。
  • 先用Mirv与先用紫杉醇组中Mirv的ORR分别为35%与34%(p=0.93)。

核心结论

  • 对于接受Mirv和周疗紫杉醇的铂耐药卵巢癌患者,治疗顺序不影响对每种药物的缓解。

研究设计与样本

  • 单中心回顾性研究,纳入62例接受过Mirv和周疗紫杉醇的铂耐药卵巢癌患者。
  • 比较两组的人口学、临床病理因素和治疗结局,用Kaplan-Meier曲线和log-rank检验比较无进展生存。

主要发现

  • Mirv的ORR为34%(21/61),周疗紫杉醇的ORR为69%(42/61)。
  • Mirv的ORR在先用Mirv组为35%,先用紫杉醇组为34%(p=0.93)。
  • 周疗紫杉醇的ORR在先用Mirv组为56%,先用紫杉醇组为73%(p=0.21)。
  • 贝伐珠单抗与Mirv联用占29%,与周疗紫杉醇联用占52%;中位FOLR-1表达为80%。

关键数值与推荐

  • 总缓解率定义为影像学完全或部分缓解和/或CA-125下降≥50%。

临床怎么用

  • 在铂耐药卵巢癌中,Mirv和周疗紫杉醇的使用顺序可不作为选择依据,但需结合个体情况。

局限性

  • 单中心回顾性设计,样本量有限,需多中心前瞻性数据确认治疗顺序对结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: With multiple clinical trials now showing survival benefit, we sought to determine whether treatment sequencing of mirvetuximab soravtansine (Mirv) and weekly paclitaxel affects response in platinum-resistant ovarian cancer (PROC). METHODS: This is a single-institution, retrospective review of PROC patients who received both Mirv and weekly paclitaxel. Demographics, clinicopathologic factors, and treatment outcomes were compared between patients based on sequence of treatment. Overall response rate (ORR) was defined as complete or partial response based on imaging and/or ≥ 50% decrease in CA-125. Kaplan Meier curves were generated to compare progression-free survival based on treatment sequencing; differences were estimated using the log-rank test. RESULTS: 62 patients received Mirv and weekly paclitaxel for PROC. Seventeen (27%) patients received Mirv first; 45 (73%) received weekly paclitaxel first. Bevacizumab was administered with Mirv in 29% of cases and with weekly paclitaxel in 52% of cases. Median FOLR-1 expression was 80%. Demographic and clinicopathologic features were not different between groups. ORR was 34% (21/61) to Mirv and 69% (42/61) to weekly paclitaxel. Response to Mirv was not different based on treatment sequencing (ORR 35% Mirv first vs 34% weekly paclitaxel first; p = 0.93). Response to weekly paclitaxel was not different based on treatment sequencing (ORR 56% Mirv first vs 73% weekly paclitaxel first, p = 0.21). CONCLUSION: For PROC patients receiving Mirv and weekly paclitaxel, order of treatment did not affect response to each agent. Further multi-institutional, prospective data is needed to confirm the impact of treatment sequencing on outcomes, as this may influence individual patients and future clinical trial design.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Haight PJ, Sakach JC, Chambers LM, et al. Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter? Gynecol Oncol. 2026. PMID: 42431171. doi:10.1016/j.ygyno.2026.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。